StockData
Obsidian Therapeutics, Inc. logo

Obsidian Therapeutics, Inc. (OBX) shareholders

OBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$12.00−0.15 (-1.23%)

Close on Nov 20, 2026Market cap $741.28MP/E –Yield –

Ownership

Who owns Obsidian Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Rajeev Shah
Joint filing with RA Capital Management, L.P. (9.70%), Peter Kolchinsky (9.70%) and 1 more
5,957,1039.70%13G (passive)Aug 3, 2026
Paradigm BioCapital Advisors LP
Joint filing with Paradigm BioCapital Advisors GP LLC (6.60%), Senai Asefaw, M.D. (6.60%) and 1 more
4,101,5766.60%13G (passive)Sep 28, 2026
Deep Track Capital, LP
Joint filing with David Kroin (5.37%), Deep Track Biotechnology Master Fund, Ltd. (5.06%)
3,315,6055.37%13G (passive)Aug 4, 2026
Novo Holdings A/S3,123,9925.10%13G (passive)Aug 3, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Madan JagasiaChief Executive Officer, Director––Nov 13, 2026
Julie B. FederChief Financial Officer––Nov 13, 2026
Parameswaran HariChief Medical Officer––Nov 13, 2026
Mark L. ReisenauerDirector––Nov 13, 2026
Maria FardisDirector––Aug 5, 2026
Peter BarrettDirector––Aug 5, 2026
Heidi HagenDirector––Aug 5, 2026
Robert W. RossDirector––Aug 5, 2026
Matthew NorkunasDirector30,9370.05%Aug 5, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
1.92%
1M shares short
Days to cover
3.9
At 0M shares a day
Change since last report
+9.6%
From 1M shares
Short volume, 20 days
60.3%
Of volume reported to FINRA

Shares sold short, last 3 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Obsidian Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 925,553 shares on Sep 23, 2026 over the last 90 days.

See a number that looks wrong?